Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Primary systemic amyloidosis.

Morie A Gertz1, S Vincent Rajkumar

  • 1Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. gertz.morie@mayo.edu

Current Treatment Options in Oncology
|June 12, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

How I treat cold agglutinin hemolytic anemia.

Clinical advances in hematology & oncology : H&O·2019
Same author

Advances in the treatment of hereditary transthyretin amyloidosis: A review.

Brain and behavior·2019
Same author

Depth of organ response in AL amyloidosis is associated with improved survival: new proposed organ response criteria.

Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis·2019
Same author

Therapy of Transthyretin Cardiomyopathy.

Journal of the American College of Cardiology·2019
Same author

The Human Microbiota in Multiple Myeloma and Proteasome Inhibitors.

Acta haematologica·2019
Same author

Ten-year survivors in AL amyloidosis: characteristics and treatment pattern.

British journal of haematology·2019
Same journal

Interaction between Regulated Cell Death Pathways and Core Cellular Processes: Unraveling the Molecular Mechanisms of Cardiotoxicity of Antitumor Drugs.

Current treatment options in oncology·2026
Same journal

Advances in Immunotherapy for Breast Cancer: Up-to-date Strategies of Immune Checkpoint Inhibitors and Therapeutic Vaccines.

Current treatment options in oncology·2026
Same journal

Recent Advances in Neoadjuvant Treatment of Anaplastic Thyroid Carcinoma: A Narrative Review.

Current treatment options in oncology·2026
Same journal

The Immunological Landscape of the Tumor Microenvironment: Implications for Immunotherapy of Unresectable and Metastatic Soft Tissue Sarcomas.

Current treatment options in oncology·2026
Same journal

Oncofertility in the Age of HER2 Blockade, Immunotherapy, PARP inhibitors, CDK4/6 inhibitors and Endocrine Treatment: Unanswered Questions in Breast Cancer.

Current treatment options in oncology·2026
Same journal

Emerging Applications of CAR-T Cell Therapy in Overcoming Resistance and Expanding Targets in Hematologic Malignancies: Insights from Recent Research.

Current treatment options in oncology·2026
See all related articles

Primary amyloidosis, a rare plasma cell disorder, involves light chain fragments causing organ damage. Early diagnosis via immunofixation and histology, with cardiac assessment for prognosis, is crucial for effective treatment.

Area of Science:

  • Hematology
  • Nephrology
  • Cardiology

Background:

  • Primary amyloidosis is a rare plasma cell dyscrasia characterized by extracellular deposition of immunoglobulin light chain fragments.
  • This deposition leads to progressive visceral organ dysfunction, including nephrotic syndrome, cardiomyopathy, and peripheral neuropathy.
  • Recognition of primary amyloidosis necessitates understanding its association with these clinical manifestations.

Purpose of the Study:

  • To outline the diagnostic approach for primary amyloidosis.
  • To identify key prognostic factors and assess treatment strategies.
  • To highlight the unique morbidities associated with stem cell transplantation in this condition.

Main Methods:

  • Screening involves serum and urine immunofixation to detect monoclonal immunoglobulin light chains.

Related Experiment Videos

  • Histological confirmation is essential, with subcutaneous fat biopsy as a minimally invasive option.
  • Cardiac involvement assessment utilizes echocardiography with Doppler studies.

    • Main Results:

    • Immunofixation is the primary screening test for detecting monoclonal light chains.
    • Subcutaneous fat biopsy offers a minimally invasive method for histological diagnosis.
    • Cardiac involvement is the most significant prognostic factor.

    Conclusions:

    • Early diagnosis and risk stratification are critical for managing primary amyloidosis.
    • Treatment options range from oral melphalan/prednisone to high-dose chemotherapy with stem cell transplantation.
    • Stem cell transplantation offers high response rates but carries unique transplantation-related morbidities.